Form 4: Astria Therapeutics Director's Options Cashed Out in BioCryst Merger

Astria Therapeutics Director Michael Kishbauch's stock options were canceled and cashed out or forfeited following the company's merger with BioCryst Pharmaceuticals.

Summary

• Michael D. Kishbauch, a Director of Astria Therapeutics, Inc. (ATXS), filed a Form 4 reporting changes in beneficial ownership related to a corporate merger.
• Astria Therapeutics, Inc. merged with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc., on January 23, 2026, making Astria a wholly-owned subsidiary of BioCryst.
• The merger agreement was dated October 14, 2025.
• In-the-money stock options (exercise price less than $13.00) held by Kishbauch became fully vested, exercisable, and were canceled in exchange for a cash payment.
• The cash payment for in-the-money options was calculated as the product of the total number of shares subject to the option and the excess of $13.00 over the option's exercise price.
• Out-of-the-money stock options (exercise price equal to or greater than $13.00) were canceled for no consideration and are not reported in this filing.
• Following the reported transactions, Kishbauch beneficially owns 0 derivative securities.
• The reported option numbers reflect an adjustment for a 1-for-6 reverse stock split effected by Astria Therapeutics on August 19, 2021.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing reports a completed merger, which is a significant corporate event. For the reporting person, some options were cashed out, which is positive, while others were canceled for no consideration, which is negative. The overall sentiment is driven by the factual reporting of a corporate action rather than performance.

Positives

• In-the-money stock options held by the director were cashed out, providing a financial payout for those holdings.
• The completion of the merger signifies a definitive corporate action, providing clarity for stakeholders of Astria Therapeutics.

Negatives

• Out-of-the-money stock options were canceled for no consideration, resulting in a loss of potential value for the director.
• Astria Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.

Risks

• The cancellation of out-of-the-money options for no consideration highlights the inherent risk of stock options expiring worthless if the underlying stock price does not exceed the exercise price by the time of a liquidity event or expiration.

Future Outlook

The filing primarily reports a past transaction related to a merger and does not provide forward-looking statements or guidance for the combined entity.

Management Comments

• The filing includes a signature by Ben Harshbarger, as attorney-in-fact for Michael Kishbauch, confirming the reported transactions.

Industry Context

This merger represents a common strategic move within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller entities to expand their pipeline, technology, or market reach. Such consolidation is a continuous trend, driven by the need for innovation and competitive advantage.

Comparison to Industry Standards

• The treatment of stock options, specifically cashing out in-the-money options and canceling out-of-the-money options, is a standard practice in M&A transactions involving equity compensation. This approach aligns with typical industry practices for handling outstanding equity awards during an acquisition.
• Without specific details on Astria's pre-merger valuation, pipeline assets, or market position, a direct comparison of the $13.00 per share merger consideration to industry-standard acquisition premiums for comparable biotech companies is not feasible based solely on this Form 4.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Astria Therapeutics: Received consideration for their shares as part of the merger (implied by the merger details, though not explicitly stated for common stock in this Form 4).
• Employees of Astria Therapeutics: Options were treated as part of the merger, indicating a change in employment structure under BioCryst.
• Michael D. Kishbauch (Director): Received cash for in-the-money options and forfeited out-of-the-money options.

Next Steps

• The filing reports a completed transaction. No future actions or milestones for Astria Therapeutics as an independent entity are mentioned, as it is now a wholly-owned subsidiary of BioCryst Pharmaceuticals.

Key Dates

Keywords

Astria Therapeutics, ATXS, BioCryst Pharmaceuticals, Merger, Stock Options, Form 4, Beneficial Ownership, Corporate Action, Director Compensation